title: Comparison of ferrous sulfate and ferrous glycinate chelate for the treatment of iron deficiency anemia in gastrectomized patients.
abstract: OBJECTIVE
  Postgastrectomy iron deficiency anemia has a variable prevalence and occurs in 20-50% of patients. Food fortification reports examining ferrous glycinate chelate have shown that it can be 2.5-3.4 times more bioavailable than ferrous sulfate, with minimal gastrointestinal symptoms. The present study was designed as a controlled experimental study including 18 gastrectomized patients with iron deficiency anemia to compare the effects of ferrous sulfate and ferrous glycinate chelate in the treatment of anemia and to evaluate the presence of side effects.
  
  
  METHODS
  Patients were divided in two groups: group 1 received ferrous sulfate (200 mg twice a day, corresponding to 80 mg of elemental iron) and group 2 received ferrous glycinate chelate (250 mg/d, corresponding to 50 mg of elemental iron) for 4 mo. Laboratory measurements were performed at baseline and after 2 and 4 mo.
  
  
  RESULTS
  Group 1 showed an apparent recovery in laboratory parameters, with increases in medium corpuscular hemoglobin (P = 0.02), serum iron (P = 0.02), and ferritin (P = 0.04), and a decrease in transferrin (P = 0.002) after 4 mo. Individualized analysis showed that only one patient using ferrous sulfate had anemia at the end of the study in contrast to six patients using ferrous glycinate. In addition, ferritin levels increased above 20 microg/L at the end of the study in seven patients using ferrous sulfate in contrast to one patient using ferrous glycinate.
  
  
  CONCLUSIONS
  Patients with iron deficiency anemia after gastrectomy treated with ferrous sulfate had better results in hematologic laboratory parameters than those who used ferrous glycinate chelate.
authors.affiliation: Cancer Hospital of Londrina, Londrina, Paraná, Brazil.
authors.forename: Erika C Mayumi
authors.initials: EC
authors.lastname: Mimura
authors.forename: José Wander
authors.initials: JW
authors.lastname: Breganó
authors.forename: Jane Bandeira
authors.initials: JB
authors.lastname: Dichi
authors.forename: Emerson Pereira
authors.initials: EP
authors.lastname: Gregório
authors.forename: Isaias
authors.initials: I
authors.lastname: Dichi
mesh_terms: D000368:Aged; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy*; D001682:Biological Availability; D005260:Female; D005293:Ferritins / Q000097:blood; D005296:Ferrous Compounds / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005743:Gastrectomy / Q000009:adverse effects*; D005998:Glycine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007408:Intestinal Absorption; D007501:Iron / Q000097:blood; D007502:Iron Chelating Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009752:Nutritional Status; D016896:Treatment Outcome
chemical_list: D005296:Ferrous Compounds; D006454:Hemoglobins; D007502:Iron Chelating Agents; C073588:bis-glycino iron II; C020748:ferrous sulfate; D005293:Ferritins; D007501:Iron; D005998:Glycine